RU94031165A - Use of arylindole-derivatives for psychosis treatment and a method of treatment - Google Patents

Use of arylindole-derivatives for psychosis treatment and a method of treatment

Info

Publication number
RU94031165A
RU94031165A RU94031165/14A RU94031165A RU94031165A RU 94031165 A RU94031165 A RU 94031165A RU 94031165/14 A RU94031165/14 A RU 94031165/14A RU 94031165 A RU94031165 A RU 94031165A RU 94031165 A RU94031165 A RU 94031165A
Authority
RU
Russia
Prior art keywords
hydrogen
alkyl
cycloalkylmethyl
cycloalkyl
alkenyl
Prior art date
Application number
RU94031165/14A
Other languages
Russian (ru)
Inventor
Кристьян Перрегор Енс
Dk]
Скарсфелт Торбен
Original Assignee
Х. Лундбекк А/С (DK)
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С (DK), Х. Лундбекк А/С filed Critical Х. Лундбекк А/С (DK)
Publication of RU94031165A publication Critical patent/RU94031165A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

FIELD: organic chemistry. SUBSTANCE: product: 6- and/or 2-substituted 1-arylindole-derivative of the general formula (I) where Ar is nonobligatory substituted phenyl or heteroaromatic group; X and X' are hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, alkylsulfonyl, alkyl- or dialkylamino, cyano, trifluoromethyl or trifluoromethylthio; or X and X' were combined to 5-7-membered carbocyclic ring; Ris hydrogen or lower alkyl at condition that if X - hydrogen or fluorine then Rdoes not hydrogen; Y is nitrogen or carbon; R is hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl or R - a substituent of the formula (Ia) or (Iв) where n - whole number = 2, 6; W is oxygen or sulfur; U is nitrogen or carbon; Z is -/CH/-, -CH=CH-, -COCH-,-CSCH- or 1,2-phenylene; V is oxygen, sulfur, CHor NR; Vis -O-R,-S-R,-CHRRor -NRRand R,Rand Rare hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl. Synthesized compounds inhibit the spontaneous activity of dopamine neurons excitement in ventricle brain region and can be used for human psychosis treatment. EFFECT: improved method of synthesis, psychosis treatment.

Claims (1)

6- и/или 2-замещенный 1-арилиндол - производный общей формулы (1), в которой Аr представляет собой необязательно замещенный фенил или гетероароматическую группу; X и X' представляют собой водород, галоген, алкил, алкокси, гидрокси, алкилтио, алкилсульфонил, алкил или диалкиламино, циан, трифторметил или трифторметилтио; или X и X' объединены в 5-7-членное карбоциклическое кольцо; R1 представляет собой водород или низший алкил при условии, что, если X - водород или фтор, то R1 не является водородом; Y представляет собой азот или углерод; R представляет собой водород, алкил, алкенил, циклоалкил или циклоалкилметил или же R-заместитель формулы (1а) или (1в ), в которой n - число 2,6, w представляет собой кислород или серу, u представляет собой азот или углерод, Z представляет собой -/СН2/m -, -CH=CH-, -СОСH2-, -CSCH2- или 1,2-фенилен; V представляет собой кислород, серу, CH2 или NR2; V1 представляет собой -O-R4, -S-R4, -CHR4R5 или -NR4R5, и R3,R4 и R5 представляют собой водород, алкил, алкенил, циклоалкил или циклоалкилметил, ингибирующий возбуждение самопроизвольной активности допаминовых нейронов в желудочковой области мозга и используемый для лечения психозов у человека.6- and / or 2-substituted 1-arylindole is a derivative of the general formula (1), in which Ar represents an optionally substituted phenyl or heteroaromatic group; X and X ′ are hydrogen, halogen, alkyl, alkoxy, hydroxy, alkylthio, alkylsulfonyl, alkyl or dialkylamino, cyan, trifluoromethyl or trifluoromethylthio; or X and X 'are combined in a 5-7 membered carbocyclic ring; R 1 represents hydrogen or lower alkyl, provided that, if X is hydrogen or fluorine, then R 1 is not hydrogen; Y represents nitrogen or carbon; R represents hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl or the R-substituent of formula (1a) or (1c) in which n is the number 2.6, w represents oxygen or sulfur, u represents nitrogen or carbon, Z represents - / CH 2 / m -, -CH = CH-, -COCH 2 -, -CSCH 2 - or 1,2-phenylene; V represents oxygen, sulfur, CH 2 or NR 2 ; V 1 is —OR 4 , —SR 4 , —CHR 4 R 5 or —NR 4 R 5 , and R 3 , R 4 and R 5 are hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylmethyl inhibiting the excitation of spontaneous dopamine activity neurons in the ventricular region of the brain and used to treat psychoses in humans.
RU94031165/14A 1991-12-23 1992-12-21 Use of arylindole-derivatives for psychosis treatment and a method of treatment RU94031165A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK2065/91 1991-12-23
DK912065A DK206591D0 (en) 1991-12-23 1991-12-23 TREATMENT OF PSYCHOSIS

Publications (1)

Publication Number Publication Date
RU94031165A true RU94031165A (en) 1996-06-20

Family

ID=8109829

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031165/14A RU94031165A (en) 1991-12-23 1992-12-21 Use of arylindole-derivatives for psychosis treatment and a method of treatment

Country Status (11)

Country Link
EP (1) EP0618799A1 (en)
JP (1) JPH07502517A (en)
AU (1) AU668537B2 (en)
CA (1) CA2126571A1 (en)
CZ (1) CZ153994A3 (en)
DK (1) DK206591D0 (en)
NO (1) NO942378L (en)
RU (1) RU94031165A (en)
SK (1) SK75794A3 (en)
WO (1) WO1993012790A1 (en)
ZA (1) ZA9210001B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554030A (en) * 1994-06-30 1996-09-10 Minnesota Mining And Manufacturing Company Method for bonding non-amalgam restorative materials to dental surfaces
UA44838C2 (en) * 1996-03-25 2002-03-15 Елі Ліллі Енд Компані METHOD OF TREATMENT OF MIGRAINE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
DK158590D0 (en) * 1990-07-02 1990-07-02 Lundbeck & Co As H indole derivatives
DK238190D0 (en) * 1990-10-03 1990-10-03 Lundbeck & Co As H DEPOT DERIVATIVES
DK8492D0 (en) * 1992-01-23 1992-01-23 Lundbeck & Co As H TREATMENT OF PSYCHOSIS

Also Published As

Publication number Publication date
ZA9210001B (en) 1994-01-13
DK206591D0 (en) 1991-12-23
EP0618799A1 (en) 1994-10-12
JPH07502517A (en) 1995-03-16
SK75794A3 (en) 1995-04-12
NO942378D0 (en) 1994-06-22
CZ153994A3 (en) 1995-06-14
NO942378L (en) 1994-06-22
WO1993012790A1 (en) 1993-07-08
CA2126571A1 (en) 1993-07-08
AU668537B2 (en) 1996-05-09
AU3345293A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
RU94044671A (en) Use of nonpeptide antagonists of tachykinin receptors
BR9916282A (en) Compound, use of a compound and method of treatment
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
PL356307A1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
RU94044453A (en) Use of 2-phenyl-3-aroylbenzothiophenes for seborrhea and acne inhibition
RU94044454A (en) Inhibitor of autoimmune diseases
ES2101858T3 (en) GENESERINE DERIVATIVES AS CHOLINESTERASE INHIBITORS.
RU94044356A (en) Use of 2-phenyl-3-aroylbenzothiophenes for thrombodulin expression increase to inhibit thrombotic disorder, for protein c activation
EE04777B1 (en) Antineoplastic compounds, pharmaceutical compositions containing them and their use
RU94037246A (en) Use of 2-phenyl-3-aroylbenzothiophenes for cartilage destruction inhibition
RU94044489A (en) Use of 2-phenyl-3-aroylbenzothiophenes for myeloperoxidase activity inhibition
NO833900L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE Naphthalene Derivatives
RU94045277A (en) Use of 2-phenyl-3-aroylbenzothiophenes for inhibition of central nervous system disorder in women at postmenopause
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition
RU98119076A (en) DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS
RU94045156A (en) Use of 2-phenyl-3-aroylbenzothiophenes for premature sexual maturation inhibition
RU94031165A (en) Use of arylindole-derivatives for psychosis treatment and a method of treatment
NO913331L (en) 4-SUBSTITUTED DIHYDROPYRIDO (4,3-D) PYRIMIDINES FOR TREATMENT OF SKIN DISORDERS.
RU2002105518A (en) Heterocyclic compounds inhibiting angiogenesis
ATE18761T1 (en) CARBAMOYLOXYBENZHYDROL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
RU94035658A (en) Use of 3-arylindole and 3-arylindazole derivatives for psychosis treatment, method of treatment
US6010685A (en) Skin protectant comprising 5-substituted and 5,5-disubstituted 3,4-dihydroxy-2(5H)-furanones
ATE229953T1 (en) NAPHTHO-IMIDAZO(1,2-A)PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
RU94044457A (en) Use of benzthiophenes for hirsutism and alopecia inhibition
RU2000102642A (en) MEDICAL MEANS AGAINST AloPETIA